Literature DB >> 11709302

Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus.

C C Chiou1, N Mavrogiorgos, E Tillem, R Hector, T J Walsh.   

Abstract

We investigated the potential synergy between two cell wall-active agents, the echinocandin FK463 (FK) and the chitin synthase inhibitor nikkomycin Z (NZ), against 16 isolates of filamentous fungi. Susceptibility testing was performed with a broth macrodilution procedure by NCCLS methods. The median minimal effective concentration (MEC) of FK against all Aspergillus species was 0.25 microg/ml (range, 0.05 to 0.5 microg/ml). For Fusarium solani and Rhizopus oryzae, MECs of FK were >512 microg/ml. The median MEC of NZ against Aspergillus fumigatus was 32 microg/ml (range, 8 to 64 microg/ml), and that against R. oryzae was 0.5 microg/ml (range, 0.06 to 2 microg/ml); however, for the other Aspergillus species, as well as F. solani, MECs were >512 microg/ml. A checkerboard inhibitory assay demonstrated synergy against A. fumigatus (median fractional inhibitory concentration index = 0.312 [range, 0.15 to 0.475]). The effect was additive to indifferent against R. oryzae and indifferent against other Aspergillus spp. and F. solani. We further investigated the pharmacodynamics of hyphal damage by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay and examined the time-sequenced changes in hyphal ultrastructure. Significant synergistic hyphal damage was demonstrated with the combination of NZ (2 to 32 microg/ml) and FK (0.03 to 0.5 microg/ml) over a wide range of concentrations (P < 0.001). The synergistic effect was most pronounced after 12 h of incubation and was sustained through 24 h. Time-sequenced light and electron microscopic studies demonstrated that structural alterations of hyphae were profound, with marked transformation of hyphae to blastospore-like structures, in the presence of FK plus NZ, while fungi treated with a single drug showed partial recovery at 24 h. The methods used in this study may be applicable to elucidating the activity and interaction of other cell wall-active agents. In summary, these two cell wall-targeted antifungal agents, FK and NZ, showed marked time-dependent in vitro synergistic activity against A. fumigatus.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11709302      PMCID: PMC90831          DOI: 10.1128/AAC.45.12.3310-3321.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

Review 1.  New drugs and novel targets for treatment of invasive fungal infections in patients with cancer.

Authors:  C C Chiou; A H Groll; T J Walsh
Journal:  Oncologist       Date:  2000

2.  Spectrophotometric method of inoculum preparation for the in vitro susceptibility testing of filamentous fungi.

Authors:  A Espinel-Ingroff; T M Kerkering
Journal:  J Clin Microbiol       Date:  1991-02       Impact factor: 5.948

Review 3.  Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development.

Authors:  A H Groll; S C Piscitelli; T J Walsh
Journal:  Adv Pharmacol       Date:  1998

4.  Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis.

Authors:  S Matsumoto; Y Wakai; T Nakai; K Hatano; T Ushitani; F Ikeda; S Tawara; T Goto; F Matsumoto; S Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

5.  Drug interaction studies of a glucan synthase inhibitor (LY 303366) and a chitin synthase inhibitor (Nikkomycin Z) for inhibition and killing of fungal pathogens.

Authors:  D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

6.  Formation of a new cell wall by protoplasts of Candida albicans: effect of papulacandin B, tunicamycin and Nikkomycin.

Authors:  M V Elorza; A Murgui; H Rico; F Miragall; R Sentandreu
Journal:  J Gen Microbiol       Date:  1987-08

7.  Characterization of the chitin biosynthesis process as a compensatory mechanism in the fks1 mutant of Saccharomyces cerevisiae.

Authors:  L J García-Rodriguez; J A Trilla; C Castro; M H Valdivieso; A Durán; C Roncero
Journal:  FEBS Lett       Date:  2000-07-28       Impact factor: 4.124

8.  In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi.

Authors:  S Tawara; F Ikeda; K Maki; Y Morishita; K Otomo; N Teratani; T Goto; M Tomishima; H Ohki; A Yamada; K Kawabata; H Takasugi; K Sakane; H Tanaka; F Matsumoto; S Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

9.  Synergistic action of nikkomycins X and Z with papulacandin B on whole cells and regenerating protoplasts of Candida albicans.

Authors:  R F Hector; P C Braun
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

10.  A rapid colorimetric assay of fungal viability with the tetrazolium salt MTT.

Authors:  S M Levitz; R D Diamond
Journal:  J Infect Dis       Date:  1985-11       Impact factor: 5.226

View more
  33 in total

1.  Efficacy of micafungin alone or in combination against systemic murine aspergillosis.

Authors:  Javier Capilla Luque; Karl V Clemons; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

Review 2.  In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection.

Authors:  William J Steinbach; John R Perfect; Wiley A Schell; Thomas J Walsh; Daniel K Benjamin
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

3.  Aspergillus fumigatus hyphal damage caused by noninvasive radiofrequency field-induced hyperthermia.

Authors:  Warna D Kaluarachchi; Brandon T Cisneros; Stuart J Corr; Nathaniel D Albert; Steven A Curley; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2013-07-08       Impact factor: 5.191

4.  Use of fluorescent probes to determine MICs of amphotericin B and caspofungin against Candida spp. and Aspergillus spp.

Authors:  Joanne Peter; Derek Armstrong; Caron A Lyman; Thomas J Walsh
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

5.  Modulation of Alternaria infectoria cell wall chitin and glucan synthesis by cell wall synthase inhibitors.

Authors:  Chantal Fernandes; Jorge Anjos; Louise A Walker; Branca M A Silva; Luísa Cortes; Marta Mota; Carol A Munro; Neil A R Gow; Teresa Gonçalves
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

Review 6.  Combination treatment of invasive fungal infections.

Authors:  Pranab K Mukherjee; Daniel J Sheehan; Christopher A Hitchcock; Mahmoud A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

7.  In vitro activity of caspofungin combined with sulfamethoxazole against clinical isolates of Aspergillus spp.

Authors:  Aya Yekutiel; Itamar Shalit; Yona Shadkchan; Nir Osherov
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

Review 8.  Micafungin.

Authors:  Blair Jarvis; David P Figgitt; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 9.  Newer systemic antifungal agents : pharmacokinetics, safety and efficacy.

Authors:  Helen W Boucher; Andreas H Groll; Christine C Chiou; Thomas J Walsh
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Fungal echinocandin resistance.

Authors:  Louise A Walker; Neil A R Gow; Carol A Munro
Journal:  Fungal Genet Biol       Date:  2009-09-19       Impact factor: 3.495

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.